1AMO at PHC Sikri, Fridabad (Haryana)
2*Associate Professor, Department of Rasashastra and Bhaishajya Kalpana, Jay Jalaram Ayurvedic Medical College, Godhra, Gujarat. Email: solankisatish04@gmail.com
3Head, Department of Rasashastra and Bhaishajya Kalpana, Institute of Teaching and Research in Ayurveda (ITRA), Jamnagar
4Department of Rasashastra and Bhaishajya Kalpana, ITRA, Jamnagar
5Head, Pharmacology Department, ITRA, Jamnagar
*Corresponding Author: Dr. Satish Solanki, Associate Professor, Department of Rasashastra and Bhaishajya Kalpana, Jay Jalaram Ayurvedic Medical College, Godhra, Gujarat, India. Email: solankisatish04@gmail.com
Background: The safety of herbo-mineral-metallic preparations is frequently questioned in the contemporary context of global standardization, particularly due to their heavy metal compositions. The United States (2002–2003) reported cases of adult lead poisoning linked to Ayurvedic medicines, even though these medications have been successfully utilized for therapeutic purposes without observable side effects for millennia.
Objective: This study aimed to evaluate the genotoxic potential of Garbhapala Rasa prepared with Shataputa Naga Bhasma — a lead-based herbo-mineral formulation — using the in vivo micronucleus (MN) assay and chromosomal aberration assay in Wistar albino rats of both sexes.
Results: Results demonstrated no discernible increase in MN frequency or DNA damage in Garbhapala Rasa-treated animals compared to vehicle control groups, confirming that the formulation was not genotoxic under the experimental conditions and test system employed.
Keywords: Garbhapala Rasa, Genotoxicity, Herbo-mineral formulation, Naga Bhasma, Chromosomal aberration, Sperm abnormality
How to cite this article: Kumar B, Solanki S, Patgiri BJ, Bedarkar P, Nariya M. Evaluation of Genotoxicity Profile of Garbhapala Rasa Prepared with Shataputa Naga Bhasma (A Lead-Based Herbo-Mineral Formulation) in Wistar Albino Rats. Int J Drug Deliv Technol. 2026;16(12s): 880-886. DOI: 10.25258/ijddt.16.12s.103
Source of support: Nil.
Conflict of interest: None